Huron Consulting Group Inc. (NASDAQ: HURN), a leading provider of business consulting services, today announced that it has entered into an agreement to acquire the assets of The Frankel Group Associates LLC, a leading life sciences consulting firm. The acquisition will expand Huron’s strategy, operations, advanced analytics, and regulatory compliance offerings to life sciences clients and to the law firms and investment firms that serve these companies.
“We are pleased to welcome Frankel Group to Huron,” said James H. Roth, president and chief executive officer, Huron Consulting Group. “Their expertise will expand the portfolio of services we provide to our pharmaceutical, medical device, and investment banking/private equity clients, while adding to the value proposition that we bring to the healthcare industry.”
The life sciences industry is undergoing significant change as a result of factors including market consolidation, healthcare reform, increased regulations, generic competition, challenging drug pipelines, and pressure on research & development (R&D) spending.
"The expansion of the current Huron Life Sciences team with the Frankel Group will enhance Huron’s capabilities to help C-suite executives in this industry address their strategic business decisions and regulatory compliance concerns in an increasingly complicated technical, commercial and regulatory environment,” said Paul Silver, managing director and Huron Life Sciences practice leader.“We are delighted to be joining Huron and expanding the deep industry knowledge and expertise of the Huron Life Sciences team,” said Barry Frankel, managing director and founder, Frankel Group. “This combination brings together a portfolio of strategic insight, science and technology depth, regulatory and compliance expertise, commercialization experience, and marketplace data and advanced analytics coupled with comprehensive risk management.” For more than 20 years, Frankel Group has served a diverse client base including global pharmaceutical, emerging bio/pharmaceutical, device and diagnostic companies as well as investment firms serving the life sciences industry. Frankel Group’s strategic solutions include Corporate Strategy, R&D Optimization, Business Development Advisory, and Commercialization Strategies.